DNLI
Denali Therapeutics Inc.
Latest close $24.17 as of Aug 4, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 6 parsed filing(s) · 3 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management CIK0001897612 | Jun 30, 2026 observed Jul 8, 2026 filed · 8d Schedule 13G amendment | Reported accumulation | 16.2M +7.7M | 12.00% 0.00 pts | $25.72 | $26.69 | $24.17 |
| T. Rowe Price Investment Management CIK0001897612 | Mar 31, 2026 observed May 15, 2026 filed · 45d Initial Schedule 13G | Initial Schedule 13G | 8.5M | 12.00% | $19.20 | $18.62 | $24.17 |
| BlackRock CIK0002012383 | Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 13.8M | $24.17 |